POU2F1 activity regulates HOXD10 and HOXD11 promoting a proliferative and invasive phenotype in Head and Neck cancer

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8803-8815

  Sharpe, Daniel J ^a   Orr, Katy S ^a   Moran, Michael ^a   White, Sharon J ^b   McQuaid, Stephen ^a,c   Lappin, Terence R ^a   Thompson, Alexander ^a   James, Jacqueline A ^a,c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Biomarker; Head and neck cancer; HOXD10; HOXD11; POU2F1

Indexed keywords

DNA; HOX PROTEIN; LUCIFERASE; TRANSCRIPTION FACTOR POU; TRANSCRIPTION FACTOR POU2F1; UNCLASSIFIED DRUG; HOMEODOMAIN PROTEIN; HOXD10 PROTEIN, HUMAN; HOXD11 PROTEIN, HUMAN; OCTAMER TRANSCRIPTION FACTOR 1; POU2F1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; BINDING SITE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DNA FLANKING REGION; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HOXD10 GENE; HOXD11 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PHENOTYPE; POU2F1 GENE; PROMOTER REGION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR INVASION; UPREGULATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HEAD AND NECK TUMOR; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TIME; TUMOR CELL LINE;

BINDING SITES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; OCTAMER TRANSCRIPTION FACTOR-1; PHENOTYPE; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84907994610     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2492     Document Type: Article

References (27)

1. Argiris A, Karamouzis MV, Raben D and Ferris RL. Head and neck cancer. Lancet. 2008; 371(9625):1695-1709.
2. Skarsgard DP, Groome PA, Mackillop WJ, Zhou S, Rothwell D, Dixon PF, O'Sullivan B, Hall SF and Holowaty EJ. Cancers of the upper aerodigestive tract in Ontario, Canada, and the United States. Cancer. 2000; 88(7):1728-1738.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010; 127(12):2893-2917.
4. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Altekruse S, Kosary C, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner M, Lewis D, Chen H, Feuer E and Cronin Ke. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD.
5. Shah N and Sukumar S. The Hox genes and their roles in oncogenesis. Nature reviews Cancer. 2010; 10(5):361-371.
6. Grier DG, Thompson A, Kwasniewska A, McGonigle GJ, Halliday HL and Lappin TR. The pathophysiology of HOX genes and their role in cancer. The Journal of pathology. 2005; 205(2):154-171.
7. Takahashi O, Hamada J, Abe M, Hata S, Asano T, Takahashi Y, Tada M, Miyamoto M, Kondo S and Moriuchi T. Dysregulated expression of HOX and ParaHOX genes in human esophageal squamous cell carcinoma. Oncology reports. 2007; 17(4):753-760.
8. Chen KN, Gu ZD, Ke Y, Li JY, Shi XT and Xu GW. Expression of 11 HOX genes is deregulated in esophageal squamous cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(3):1044-1049.
9. Hassan NM, Hamada J, Murai T, Seino A, Takahashi Y, Tada M, Zhang X, Kashiwazaki H, Yamazaki Y, Inoue N and Moriuchi T. Aberrant expression of HOX genes in oral dysplasia and squamous cell carcinoma tissues. Oncology research. 2006; 16(5):217-224.
10. Soshnikova N, Dewaele R, Janvier P, Krumlauf R and Duboule D. Duplications of hox gene clusters and the emergence of vertebrates. Developmental biology. 2013; 378(2):194-199.
11. Kel AE, Gossling E, Reuter I, Cheremushkin E, Kel-Margoulis OV and Wingender E. MATCH: A tool for searching transcription factor binding sites in DNA sequences. Nucleic acids research. 2003; 31(13):3576-3579.
12. Zhao FQ, Zheng Y, Dong B and Oka T. Cloning, genomic organization, expression, and effect on beta-casein promoter activity of a novel isoform of the mouse Oct-1 transcription factor. Gene. 2004; 326:175-187.
13. Shakya A, Kang J, Chumley J, Williams MA and Tantin D. Oct1 is a switchable, bipotential stabilizer of repressed and inducible transcriptional states. The Journal of biological chemistry. 2011; 286(1):450-459.
14. Reymann S and Borlak J. Transcription profiling of lung adenocarcinomas of c-myc-transgenic mice: identification of the c-myc regulatory gene network. BMC systems biology. 2008; 2:46.
15. Wang D, Yamamoto S, Hijiya N, Benveniste EN and Gladson CL. Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions. Oncogene. 2000; 19(50):5801-5809.
16. Kim YM, Ko CB, Park YP, Kim YJ and Paik SG. Octamer motif is required for the NF-kappaB-mediated induction of the inducible nitric oxide synthase gene expression in RAW 264.7 macrophages. Molecules and cells. 1999; 9(1):99-109.
17. Jin T and Li H. Pou homeodomain protein OCT1 is implicated in the expression of the caudal-related homeobox gene Cdx-2. The Journal of biological chemistry. 2001; 276(18):14752-14758.
18. Wang L, Chen S, Xue M, Zhong J, Wang X, Gan L, Lam EK, Liu X, Zhang J, Zhou T, Yu J, Jin H and Si J. Homeobox D10 gene, a candidate tumor suppressor, is downregulated through promoter hypermethylation and associated with gastric carcinogenesis. Mol Med. 2012; 18:389-400.
19. Sasayama T, Nishihara M, Kondoh T, Hosoda K and Kohmura E. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. International journal of cancer Journal international du cancer. 2009; 125(6):1407-1413.
20. Carrio M, Arderiu G, Myers C and Boudreau NJ. Homeobox D10 induces phenotypic reversion of breast tumor cells in a three-dimensional culture model. Cancer research. 2005; 65(16):7177-7185.
21. Terui K, Kitazawa J, Takahashi Y, Tohno C, Hayashi Y, Taketani T, Taki T and Ito E. Successful treatment of acute myelomonocytic leukaemia with NUP98-HOXD11 fusion transcripts and monitoring of minimal residual disease. British journal of haematology. 2003; 120(2):274-276.
22. Morgan R, Boxall A, Harrington KJ, Simpson GR, Gillett C, Michael A and Pandha HS. Targeting the HOX/PBX dimer in breast cancer. Breast cancer research and treatment. 2012; 136(2):389-398.
23. Morgan R, Boxall A, Harrington KJ, Simpson GR, Michael A and Pandha HS. Targeting HOX transcription factors in prostate cancer. BMC urology. 2014; 14:17.
24. Morgan R, Pirard PM, Shears L, Sohal J, Pettengell R and Pandha HS. Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. Cancer research. 2007; 67(12):5806-5813.
25. Morgan R, Plowright L, Harrington KJ, Michael A and Pandha HS. Targeting HOX and PBX transcription factors in ovarian cancer. BMC cancer. 2010; 10:89.
26. Thomas GJ, Poomsawat S, Lewis MP, Hart IR, Speight PM and Marshall JF. alpha v beta 6 Integrin upregulates matrix metalloproteinase 9 and promotes migration of normal oral keratinocytes. J Invest Dermatol. 2001; 116(6):898-904.
27. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, James CR, Farragher SM, Mulligan JM, Scott AN, Dervan PA, Johnston PG, Couch FJ, Daly PA, Kay E, McCann A, et al. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst. 2007; 99(22):1683-1694.